Strong Buy Rating on Mind Medicine Backed by Positive Developments in MM120 Trials and Solid Financial Standing
Lykos Laying off 75% of Workforce Following FDA Rejection of Psychedelic Drug for PTSD
Maxim Group Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $18
Strong Financial Position and Promising Clinical Trials Underpin Buy Rating for Mind Medicine
Small Cap Stocks: Mind Medicine (MNMD) Is a Psychedelic Biotechnology Bet
Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript Summary
Express News | Mind Medicine (MindMed) Inc : RBC Cuts Target Price to $20 From $22
Leerink Partners Maintains Mind Medicine(MNMD.US) With Buy Rating
Buy Rating Affirmed for Mind Medicine With Promising Phase 3 Trials on the Horizon
Express News | Mind Medicine Inc: Strong Financial Position With a Cash Runway Into 2027 Based on Current Operating Plan
MindMed Readying Phase III Trials for LSD Therapy to Treat Anxiety
10-Q: Q2 2024 Earnings Report
Express News | Mind Medicine Q2 2024 GAAP EPS $(0.26) Beats $(0.33) Estimate, With A Cash Balance Of $243.1M And Recently Closed Public Offering Of $75M In Gross Proceeds Is Expected To Provide Cash Runway Into The First Half Of 2026
Express News | Mind Medicine (MindMed) Inc: Extends Cash Runway Into 2027
Mind Medicine MindMed 2Q Loss/Shr 26c >MNMD
Mind Medicine MindMed 2Q Loss $5.85M >MNMD
Express News | MindMed Q2 Operating Expenses USD 24.458 Million
Express News | MindMed Q2 Net Income USD -5.854 Million
Express News | MindMed Q2 Basic EPS USD -0.08
Express News | MindMed Q2 Income From Operations USD -24.458 Million